FDA 483 - Generichem Corporation - June 08, 2022

An FDA inspection of Generichem Corporation, a labeler/relabeler in Totowa, NJ, revealed significant deficiencies in its quality control unit and investigation procedures. The firm failed to establish written responsibilities with its API manufacturer and did not adequately document customer inquiries or investigations into product discrepancies. These findings indicate a lack of robust quality management practices.